{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=normal+saline+solution+placebo&page=30", "query": { "intervention": "normal saline solution placebo", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 1623, "total_pages": 163, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=normal+saline+solution+placebo&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=normal+saline+solution+placebo&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T18:12:49.232Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03945292", "title": "Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alpha 1-Antitrypsin Deficiency" ], "interventions": [ { "name": "Fazisiran Injection", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Arrowhead Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 40, "start_date": "2019-08-07", "completion_date": "2023-09-18", "has_results": true, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-11-15T18:12:49.232Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03945292" }, { "nct_id": "NCT04218695", "title": "Prophylactic Antibiotics in Admitted Cirrhotics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cirrhosis, Liver" ], "interventions": [ { "name": "Ceftriaxone", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2020-08-24", "completion_date": "2021-08-28", "has_results": true, "last_update_posted_date": "2023-03-03", "last_synced_at": "2026-11-15T18:12:49.232Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04218695" }, { "nct_id": "NCT02770716", "title": "Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatorenal Syndrome" ], "interventions": [ { "name": "Terlipressin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mallinckrodt", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2016-07-13", "completion_date": "2019-07-24", "has_results": true, "last_update_posted_date": "2022-11-29", "last_synced_at": "2026-11-15T18:12:49.232Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02770716" }, { "nct_id": "NCT05375838", "title": "A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "SARS-CoV-2", "Influenza" ], "interventions": [ { "name": "mRNA-1073", "type": "BIOLOGICAL" }, { "name": "mRNA-1010", "type": "BIOLOGICAL" }, { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 550, "start_date": "2022-05-13", "completion_date": "2022-12-29", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-11-15T18:12:49.232Z", "location_count": 14, "location_summary": "Hollywood, Florida • Peoria, Illinois • Sioux City, Iowa + 9 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Norfolk", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05375838" }, { "nct_id": "NCT02492126", "title": "Esophageal Motility in Reflux Induced Cough", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cough" ], "interventions": [ { "name": "Citric Acid", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 87, "start_date": "2016-01", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2020-10-30", "last_synced_at": "2026-11-15T18:12:49.232Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02492126" }, { "nct_id": "NCT03110900", "title": "Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Agitation,Psychomotor", "Haloperidol Causing Adverse Effects in Therapeutic Use", "Lorazepam Causing Adverse Effects in Therapeutic Use", "Loxapine Causing Adverse Effects in Therapeutic Use" ], "interventions": [ { "name": "Haloperidol + lorazepam", "type": "DRUG" }, { "name": "Loxapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2, "start_date": "2017-09-30", "completion_date": "2018-04-04", "has_results": true, "last_update_posted_date": "2018-06-11", "last_synced_at": "2026-11-15T18:12:49.232Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03110900" }, { "nct_id": "NCT01473264", "title": "Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Respiratory Distress Syndrome in Premature Infant", "Bronchopulmonary Dysplasia" ], "interventions": [ { "name": "recombinant human CC10 (rhCC10)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clarassance, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "24 Weeks", "maximum_age": "29 Weeks", "sex": "ALL", "summary": "24 Weeks to 29 Weeks" }, "enrollment_count": 22, "start_date": "2000-01", "completion_date": "2003-12", "has_results": false, "last_update_posted_date": "2011-11-17", "last_synced_at": "2026-11-15T18:12:49.232Z", "location_count": 4, "location_summary": "Wilmington, Delaware • Baltimore, Maryland • Mineola, New York", "locations": [ { "city": "Wilmington", "state": "Delaware" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01473264" }, { "nct_id": "NCT03836664", "title": "A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Migraine" ], "interventions": [ { "name": "Timolol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2017-02-27", "completion_date": "2018-04-14", "has_results": true, "last_update_posted_date": "2019-07-02", "last_synced_at": "2026-11-15T18:12:49.232Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03836664" }, { "nct_id": "NCT02771509", "title": "Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Kidney Injury" ], "interventions": [ { "name": "ANG-3777", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Angion Biomedica Corp", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2017-02-24", "completion_date": "2021-08", "has_results": false, "last_update_posted_date": "2021-07-15", "last_synced_at": "2026-11-15T18:12:49.232Z", "location_count": 23, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02771509" }, { "nct_id": "NCT04537208", "title": "Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "COVID-19 (Healthy Volunteers)" ], "interventions": [ { "name": "CoV2 preS dTM-AF03 (low-dose)", "type": "BIOLOGICAL" }, { "name": "CoV2 preS dTM-AF03 (high-dose)", "type": "BIOLOGICAL" }, { "name": "CoV2 preS dTM-AS03 (low-dose)", "type": "BIOLOGICAL" }, { "name": "CoV2 preS dTM-AS03 (high-dose)", "type": "BIOLOGICAL" }, { "name": "CoV2 preS dTM (high-dose) without adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo (0.9% normal saline)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 441, "start_date": "2020-09-03", "completion_date": "2021-11-19", "has_results": true, "last_update_posted_date": "2025-09-17", "last_synced_at": "2026-11-15T18:12:49.232Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Rolling Hills Estates, California • Hollywood, Florida + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Rolling Hills Estates", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04537208" } ] }